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Clinical relevance of bcl2(MBR)IJ,H rearrangement
detected by polymerase chain reaction in the peripheral
blood of patients with follicular lymphoma
F Bertoni, G Bosshard, E Roggero, E Ceresa, F Cavalli and E Zucca
Servizio Oncologico Cantonale, Ospedale San Giovanni, CH-6500 Bellinzona, Switzerland
Summary We evaluated the prognostic role of peripheral blood polymerase chain reaction (PCR) assay for detection of the bcl-2(MBR)/JH
rearrangement in 59 patients with follicular lymphoma (FL) treated at our centre since 1989. Thirty-five (59%) patients were bcl-2/JH positive
and 24 (41%) were negative in the peripheral blood at diagnosis. Peripheral blood bcl-2/JH rearrangement detection at diagnosis had no
relation to overall survival (OS) and time to progression (TTP). Peripheral blood PCR assay was performed post treatment in 17 patients who
were bcl-2/JH positive at diagnosis. Fourteen of the patients (82%, 95% Cl 56-96%) became bcl-2/JH negative. Nine of these patients were
further analysed during follow-up and, after several months, circulating cells carrying the bcl-2/JH rearrangement reappeared in five of the nine
patients. Peripheral blood clearance of bcl-2/JH-positive cells was correlated with better overall survival (log-rank P < 0.05) but not with TTP.
Our data confirmed that bcl-2(MBR)/JH rearrangement detection by PCR at diagnosis is not a prognostic factor in follicular lymphoma. In our
series, clearance of circulating bcl-2/JH-positive cells appeared to correlate with better overall survival. Post-treatment examination of the
peripheral blood by PCR may have clinical relevance for prediction of the survival pattern of the patients.
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The majority offollicular lymphomas (FL) and 20-30% ofdiffuse
large B-cell lymphomas carry the t(14;18) (q32;q21) chromosomal
translocation which juxtaposes the bcl-2 gene on chromosome
18q21 to the joining region (JH) of the immunoglobulin heavy
chain gene on chromosome 14q32. This leads to overexpression of
afunctionally normal bcl-2 protein, conferring a growth advantage
on the neoplastic cells (Yunis et al, 1987; Corbally et al, 1992;
Croce, 1993; Mrozek & Bloomfield, 1993). The breakpoint
regions on chromosome 18 are clustered in two areas, major
breakpoint region (MBR) in 60% and minor cluster region (mcr)
in 10-20% (Weiss et al, 1987; Cotter et al, 1990; Cotter et al,
1991) and are readily detectable by polymerase chain reaction
(PCR) using the consensus JH primers and primers specific to one
or more breakpoint regions. This makes possible a sensitive and
reproducible assay for detection ofthe bcl-2/JH rearrangement at a
level of 1 in 105 cells. The clinical significance of detecting the
t(14;18) translocation in patients with FL remains controversial
(Pezzella et al, 1992; Tilly et al, 1994; Johnson et al, 1995;
Whang-Peng et al, 1995). Furthermore, the same rearrangement
can be detected, although at very low levels, in healthy people, in
whom it does not predispose to malignancy (Liu et al, 1994; Bell
etal, 1995; Ji etal, 1995; Limpens et al, 1995; Dolken et al, 1996).
The peripheral blood is readily accessible and it has been
suggested that it has a good degree of concordance with bone
marrow (Hickish et al, 1991; Yuan et al, 1993) and with lymph
node tissue (Lopez-Guillermo et al, 1996). We decided to evaluate
prospectively the prognostic significance ofbcl-2/JH rearrangement
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detection by PCR in the blood of patients with FL treated at
our centre.
MATERIALS AND METHODS
Peripheral blood and/or bone marrow samples from fifty-nine
HIV-negative patients with FL, histologically diagnosed by the
International Working Formulation (IWF) (The Non-Hodgkin's
Lymphoma Pathologic Classification Project, 1982) and the
Revised European-American Classification of Lymphoid
Neoplasms (Harris et al, 1994), were analysed in our department
for the presence of the bcl-2(MBR)/JH rearrangement using PCR
assay during the period from January 1989 until December 1995.
All of the patients underwent a complete staging procedure,
including physical examination, chest radiography, abdominal
computerized tomography (CT) scan, routine haematology with
bone marrow biopsy and aspiration and peripheral blood and bone
marrow sample collection for assessment by PCR of the presence
ofthe bcl-2(MBR)/JH rearrangement.
Clinical stage was defined according to the Ann Arbor classifi-
cation. Performance status (PS) was evaluated by the Eastern
Cooperative Oncology Group (ECOG) scale. Bulky disease was
defined as a mass > 10 cm. The International Prognostic Index
(IPI) was calculated according to the original paper (The
International Non-Hodgkin's Lymphoma Prognostic Factors
Project, 1993).
Peripheral blood samples were collected during the initial eval-
uation in all patients and in 17 patients also after treatment.
DNA extraction
Whole-blood samples (10 ml) were treated with lysis buffer
(0.32 M sucrose, 10 mM Tris-HCl pH 7.5, 5 mm magnesium
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Table 1 Characteristics of the 59 patients with follicular lymphoma according to the detection by PCR of bcl-2(MBR)/JH rearrangements in
the peripheral blood
Bcl-2/JH-negative Bcl-IJH-positive P(X2-test)
blood (24 patients) blood (35 patients)
Age (years) NS
<60 15 (63)a 23 (66)a
>60 9 (37) 12 (34)
Sex NS
Female 11 (46) 10 (29)
Male 13 (54) 25 (71)
Histology (according to the WF) 0.040
B 7 (29) 20 (57)
C 15 (63) 15 (43)
D 2 (8) 0
Histological progression 1 (4) 2 (6) NS
Ann Arbor stage NS
1 7 (29) 6 (17)
11 6 (25) 3 (9)
III 4 (17) 9 (26)
IV 7 (29) 17 (49)
Systemic symptoms NS
A 24 (100) 34 (97)
B 0 1 (3)
Performance status NS
ECOG 0-1 24 (100) 32 (91)
ECOG > 1 0 3 (9)
Bulky disease NS
Absent 22 (92) 32 (91)
Present 2 (8) 3 (9)
Serum lactate dehydrogenase NS
Normal 18/23 (78) 28/32 (87)
Elevated 5/23 (22) 4/32 (13)
Unknown 1 3
Serum f2-microglobulin NS
Normal 13/20 (65) 21/26 (81)
Elevated 7/20 (35) 5/26 (19)
Unknown 4 9
Lymph nodes only 12 (50) 12 (35) NS
Bone marrow involvement NS
Absent 17 (71) 19 (54)
Present 7 (29) 16 (46)
Liver involvement NS
Absent 23 (96) 32 (91)
Present 1 (4) 3 (9)
Spleen involvement NS
Absent 21 (87) 28 (80)
Present 3 (13) 7 (20)
More than two extra-nodal sites 4 (17) 9 (25) NS
International Prognostic Index NS
Low risk 15/23 (65) 18/32 (56)
Low-intermediate risk 6/23 (26) 9/32 (28)
High-intermediate risk 2/23 (9) 4/32 (13)
High risk 0 1/32 (3)
Unknown 1 3
Initial therapeutic approach NS
Wait and see 9 (38) 13 (37)
Chlorambucil with or without prednisone 7 (29) 12 (34)
CVP 1 (4) 2 (6)
CHOP-like 4 (17) 3 (9)
Local treatment only (radiotherapy or surgery) 3 (12) 5 (14)
aNumbers in parentheses are percentages.
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chloride, 1% Triton X-100) to remove red cells. Pellets obtained by
centrifuging (15 min at 3000 r.p.m.) were then incubated overnight
at 37°C with 100 mm sodium chloride, 25 mM EDTA, 0.5% sodium
dodecyl sulphate (SDS) and 200 jg ml-' proteinase K (Sigma,
St Louis, MO, USA). DNA was extracted by phenol-chloroform
and precipitated with ethanol.
If small pellets were obtained after red cell lysis, they were
resuspended in a digestion buffer [1 x PCR buffer, 0.5% Tween 20
and 200 gg ml-' proteinase K (Sigma) for 100 ,ul] and incubated
at 56°C for 90 min and then at 94°C for 20 min to inactivate
enzymatic activity. DNA presence was tested with PCR assay
using PCO4 (5'-CAACTTCATCCACGTTCACC-3') and GH20
(5'-GAAGAGCCAAGGACAGGTAC-3') primers (Perkin-Elmer,
Norwalk, CT, USA), which amplify a 268-bp segment of the ,-
globin gene.
PCR methodology
One and a half micrograms ofphenol-chloroform-extracted DNA
or 5 ,ul of digestion buffer-extracted DNA were analysed. PCR
reactions were performed in 50-il volumes including 1 x PCR
buffer (50 mm potassium chloride, 10 mM Tris-HCl pH 8.4,
2.5 mm magnesium chloride), 200 jM of each deoxynucleotide
(Pharmacia, Uppsala, Sweden), 25 pmol ofeach primer and 1.25 U
of Taq polymerase (Gibco, Gaithersburg, MD, USA).
The first round ofthe nested PCR amplification was performed
for 30 cycles in a Perkin Elmer Cetus Thermal Cycler 480 with
the outer primers 5'-ACCTGAGGAGACGGTGACC-3' for the
JH region and 5'-CAGCCTTGAAACATTGATGG-3' for MBR
(Pharmacia Biotech, Roosendaal, The Netherlands). Each cycle
included 45 s ofdenaturation at 95°C, 1 min of annealing at 60°C
and 2 min ofextension at 72°C. A touch-down PCR technique was
used starting from an annealing temperature of 60°C, which was
decreased every other cycle by 1°C for the first eight cycles.
Five microlitres ofthe first-round DNA product was reamplified
for 30 cycles with inner primers 5'-CAGGGTTCCTTGGC-
CCCAG-3' for the JH region and 5'-AGTTGCTTTACGTGGC-
CTGT-3' for the MBR (Pharmacia Biotech). Each cycle included
45 s ofdenaturation at 94°C, 1 min ofannealing at 57°C and 1 min
ofextension at 720C.
DNA amplification was always started with 10 min of initial
denaturation at 950C and finished with 10 min of final extension
at 720C.
Patient samples were always analysed together with the human
B-cell lymphoma cell line DoHH2 (provided by Dr FE Cotter,
London, UK) as positive control and the reaction mixture with no
DNA as negative control. The appropriate procedures to avoid
contamination were always followed.
Ten microlitres of the second-round product were loaded in
2% agarose electrophoresis gel containing ethidium bromide and
visualized under ultraviolet light.
Statistical methods
Overall survival (OS) was defined as the time from the day ofdiag-
nosis until death from any cause oruntil the lastfollow-up. Time to
progression (TTP) was measured as the time from the diagnosis
until progression, relapse after response or death from lymphoma.
Actuarial survival probabilities were calculated using the life-table
method. Survival curves were estimated using the Kaplan-Meier
method and differences were evaluated using the log-rank test. The
STATA software package (Computing Resource Center, Santa
Monica, CA, USA) was used for all statistical procedures.
RESULTS
After PCR analysis of peripheral blood samples, 35 of 59 (59%)
cases ofFL werebcl-2(MBR)/JH positive and 24 (41%) were nega-
tive at diagnosis. Patient characteristics are listed in Table 1. The
two groups had similar clinical, biological and therapeutic charac-
teristics with the exception of the histological subtypes: the
number of bcl-2(MBR)/JH-positive patients was significantly
higher in the follicular predominantly small cleaved cell
lymphoma subgroup (IWF-B).
The median follow-up time was 46 months. For the group as a
whole, the projected 5-year OS was 83% (95% CI 68-91%) and
the 5-year TTP 39% (95% CI 23-55%).
The presence of the bcl-2/JH rearrangement in the peripheral
blood at diagnosis was associated neither with a significantly
worse OS (P = 0.751) nor with shorter TTP (P = 0.867).
Among the prognostic factors analysed, ECOG PS > 1 was
significantly associated with reduced OS (P < 0.0001) and TTP
(P < 0.0001); age > 60 years and liver involvement were signifi-
cantly associated with worse OS (P = 0.0003 and P = 0.0352
respectively). High-risk according to the IPI was associated with
worse OS and TTP (both P<0.0001).
For 17 patients who had a bcl-2/JH rearrangement detectable at
diagnosis in both peripheral blood and bone marrow, peripheral
blood PCR assay was performed after treatment. Fourteen patients
(82%; 95% CI 56-96%) became bcl-2/JH negative; 9 of these 14
patients were further analysed during follow-up and circulating
cells carrying the bcl-2/JH rearrangement reappeared infive ofthem
after several months (median 16, range 7-28 months). Five patients
remained negative after a median follow-up of 23 months (range
16-43 months). Clearance ofcirculating bcl-2/JH-positive cells was
correlated with better OS (P = 0.04) but not with longerTTP.
DISCUSSION
Bcl-2 protein is a potent blocker of programmed cell death
(Hockenberry et al, 1990).
More than 90% of FL overexpress bcl-2 protein because of the
t(14;18) translocation. The clinical significance ofthe detection of
this translocation by PCR is debatable.
Some authors (Johnson et al, 1995; Whang-Peng et al, 1995)
show a better clinical outcome for t(14;18)-positive cases, while
others (Pezzella et al, 1992; Tilly et al, 1994) fail to demonstrate
any prognostic significance for either both bcl-2 gene rearrange-
ment or bcl-2 protein expression.
Our series of 59 cases confirmed the absence of prognostic
significance of bcl-2(MBR)/JH detection by PCR at diagnosis.
These data are not surprising as the majority of the patients with
FL have circulating t(14;18) B-cells (Gribben et al, 1991;
Berinstein et al, 1993; Lambrechts et al, 1993), and even healthy
people may harbour translocated clones (Liu et al, 1994; Bell et al,
1995; Ji et al, 1995; Limpens et al, 1995; Dolken et al, 1996).
Even the significance of 'molecular remission', after both
conventional or myeloablative chemotherapy, is a matter of
debate. Price et al (1991) and Finke et al (1993) reportthe presence
of t(14;18)-positive circulating cells in patients in long-term
complete remission after conventional chemotherapy. Lambrechts
et al (1994) show no correlation between the presence or absence
British JournalofCancer(1997) 76(1), 36-39 0CancerResearch Campaign 1997Monitoring bcl-2 rearrangement in follicular lymphoma 39
ofperipheral blood positive cells and clinical outcome. Gribben et
al (1994) report that the reappearance of circulating positive cells
is strongly associated with relapse after myeloablative therapy.
Similar results are shown by Hardingham et al (1995). Recently,
50-70% of cases with peripheral blood clearance have been
reported after non-myeloablative therapy, both in responders and
in non-responders (Betticher et al, 1996; Cabanillas et al, 1996).
In our series, positive cases with clearance ofcirculating bcl-2/J -
positive cells appeared to have a better OS but not a longer TTP.
However, because of the prolonged natural course of the disease, a
longer follow-up is necessary before any definitive conclusion.
Peripheral blood is the most easily accessible tissue for follow-
up analysis ofbcl-2/JH rearrangements. Our study suggests that the
loss of t(14;18) detection by PCR in the blood bodes well for
survival. It may be concluded that post-treatment examination of
the peripheral blood in FL by PCR may have clinical relevance in
predicting the survival pattern of patients and for monitoring
response to treatment. However, the use of a standardized PCR
method would be needed in the future to allow comparison of
results from different institutions, as current data on the clinical
value of molecular remission are still controversial.
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